Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 11/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
| ▸ | AR | P10275 | 7/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021063 | 0.89 | PGR (0.46) | PGRKCNH2CYP2C9CYP2D6AR | |
| SCHEMBL3443507 | 0.88 | PGR (0.50) | PGRKCNH2CYP2C9CYP2D6AR | |
| SCHEMBL3029068 | 0.87 | PGR (0.37) | PGRKCNH2AR | |
| SCHEMBL3031759 | 0.86 | PGR (0.41) | PGRKCNH2CYP2C9CYP2D6AR | |
| SCHEMBL3025465 | 0.85 | PGR (0.38) | PGRKCNH2AR | |
| SCHEMBL3025100 | 0.79 | PGR (0.46) | PGRKCNH2AR | |
| SCHEMBL3021238 | 0.79 | PGR (0.52) | PGRCYP2C9ARL3MBTL1 | |
| SCHEMBL3443929 | 0.77 | PGR (0.47) | PGRKCNH2AR | |
| SCHEMBL3031568 | 0.76 | PGR (0.52) | PGRKCNH2AR | |
| SCHEMBL3033988 | 0.75 | PGR (0.52) | PGRKCNH2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC2, PGRMC1 | PGR 1/4885KCNH2 2798/4885CYP2C9 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.